Marabio Systems, which developed the first blood test to detect a biological subtype of autism in mothers, recently announced it raised $19m in a series A funding round led by MAK Capital One, LLC.
The northern California-based company plans to use the proceeds to develop a precision immunology platform to diagnose autism and initial development of potential therapeutic interventions to neutralize